Page 19

eMag_264548_NCS Currents_December2016_3

The MOCHA Study is Heating Up! By David Matthew Greer, MD, MA, FNCS The MOCHA (Multimodal Outcome CHAracterization in Cardiac Arrest) Study is a prospective, multi-center international study of prognostication after cardiac arrest using an innovative approach neurologic outcome assessment by reducing the impact of the self-fulfilling prophecy. MOCHA has 3 main objectives: 1. To standardize the evaluation of post-cardiac arrest patients with validated tests (clinical, electrophysiologic, biochemical markers and imaging) at appropriate time points; 2. To encourage more time to allow for delayed recovery in patients with an uncertain prognosis; and 3. To establish a network for future prospective studies evaluating therapeutic interventions in defined subpopulations of cardiac arrest survivors. It is important to note several important features of the study. First, centers are not expected to perform testing that is outside the scope of their standard care; however, guidance will be provided as to how to perform specific tests, as well as the appropriate timing of their performance. Second, centers will be encouraged to allow additional time for recovery, especially in cases in which the outcome is uncertain, or in patients in whom there are no overwhelming systemic comorbidities that might sway toward early WLST. Third, the study is international, and will include many centers in countries that traditionally have very little early WLST. We are excited that the launch of MOCHA has begun, with over 30 sites in the US and internationally, including key locations such as Brazil and Korea, where different practice patterns may help to avoid the self-fulfilling prophesy bias. We are quite interested in recruiting more centers, especially those with high volumes of cardiac arrest as well as neurointensivists motivated to study this disease. We are using a robust data collection tool using an online data entry system, as well as a centralized data warehouse for electrophysiological (EEG and SSEP) and neuroimaging (CT and MRI) data for central analysis. Sites will be credited with authorship based on their level of participation, and will be encouraged to take ownership of individual projects that are of interest to them, for which the database could be utilized. Neuroprognostication is one of the core functions of neurointensivists, and prognostication after cardiac arrest is perhaps the most homogenous and best studied of all major cerebral injuries. However, based on limitations in the data thus far, prognostication of patients with hypoxic-ischemic encephalopathy is potentially inaccurate, biased and commonly premature. There is much to be gained by studying this disease well, as the tools utilized and lessons learned may translate into better methods of prognostication in many other disease states in Neurocritical care. 19 PONS CONTINUING EDUCATION ACCREDITATION This activity has been planned and implemented by Ciné-Med and the Neurocritical Care Society. Ciné-Med is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC). Physicians Ciné-Med designates this enduring material for a maximum of 9.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Nurses This activity provides up to 9.5 contact hours for nurses. Pharmacists This program has been accredited for up to .95 CEU (9.5 contact hours) of continuing education credit. MEMBERS SAVE 20% PONS PRICING INDIVIDUAL PRESENTATIONS: Purchase Individual Presentations- With Continuing Education or Without! Member, Non-CE, Individual Presentation: $6 Non-Member, Non-CE, Individual Presentation: $8 Member, CE, Individual Presentation: $12 12 Non-Member, CE, Individual Presentation: $15 BUNDLE PACKAGE: Purchase the 12-part Series in a bundle and SAVE! Member, Non-CME, Package of 12: $58 58 Non-Member, Non-CME, Package of 12: $77 Member, CME, Package of 12: $115.20 Non-Member, CME, Package of 12: $144 BUNDLE & SAVE 20% Cine-Med verifi es that sound education principles have been demonstrated in the development of this educational o„ ering as evidenced by the review of its objectives, teaching plan, faculty, and activity evaluation process. Cine-Med does not endorse or support the actual opinions or material content as presented by the speaker(s) and/or sponsoring organization. Cine-Med adheres to accreditation requirements regarding industry support of continuing medical education. Disclosure of the planning committee and faculty’s commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or any discussion of any o„ -label, experimental, or investigational uses of drugs or devices in their presentations. All Cine-Med and Neurocritical Care Socieity employees in control of content have indicated that they have no relevant fi nancial relationships to disclose


eMag_264548_NCS Currents_December2016_3
To see the actual publication please follow the link above